Biodesix, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$87M
↓-10.0% -$10Mvs FY2024
Total Liabilities
$90M
↑+17.8% +$14Mvs FY2024
Cash
$19M
↓-27.7% -$7Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $87M | $97M |
| Current Assets | $33M | $39M |
| Cash | $19M | $26M |
| ST Investments | $0 | $0 |
| Receivables | $9M | $9M |
| Inventory | $0 | $0 |
| Other Current | $4M | $5M |
| Non-Current Assets | $55M | $58M |
| PPE | $25M | $28M |
| Goodwill | $15M | $15M |
| Intangibles | $4M | $6M |
| Investments | $0 | $0 |
| Other Non-Current | $11M | $9M |
| Total Liab+Eq | $87M | $97M |
| Current Liab. | $17M | $14M |
| Accounts Payable | $3M | $2M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $961K | $678K |
| Other CL | $13M | $11M |
| Non-Current Liab. | $73M | $62M |
| Long-Term Debt | $50M | $40M |
| Other LT Liab. | $22M | $22M |
| Equity | $-2M | $21M |
| Retained Earnings | $498M | $462M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · BDSX · Comparing FY2025 vs FY2024